Drug Trial Radar · NCT04640545
A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
Last checked: Nov 19, 2026Latest source record: May 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
79
Actual
Start
May 12, 2020
Primary completion
Aug 19, 2024
Study completion Aug 19, 2024
Sponsor
- Lead sponsor
- Nanjing Leads Biolabs Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Nov 23, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase I clinical study evaluating LBL-007 in the treatment of subjects with advanced solid tumors
Conditions
- Advanced Melanoma
Interventions
LBL-007Drug
LBL-007 will be administered intravenously every two weeks (Q2W) .
ToripalimabDrug
Toripalimab Injection will be administered by intravenously (Q2W) .
Axitinib TabletsDrug
Axitinib Tablets On-demand administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjcects with adverse events and serious adverse eventsTime frame: All subjects signed the informed consent form to the completion of the follow-up period of drug withdrawal (28+7 days after drug withdrawal or before the start of new anti-tumor therapy)
- Maximum tolerated dose (MTD)Time frame: During the first two Cycles(each cycle is 14 days)
- Dose-limiting toxicities (DLT)Time frame: During the first two Cycles(each cycle is 14 days)
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Fujian Cancer Hospital
Fuzhou, Fujian, China
Union Hospital Tongji Medical College Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Nanjing Drum Tower Hospital
Nanjing, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.